A gene therapy restores hearing in a child born deaf

Children born without a working copy of one gene (OTOF, which makes a protein the inner ear's hair cells need to pass sound on to the nerve) are profoundly deaf from birth. A working copy, injected into the inner ear once, let most of the children in the first trial hear speech within weeks. It is the first time a sense missing from birth has been restored by changing a child's genes.

What would count

A child born deaf because of a named gene, given a working copy of that gene in the inner ear, afterwards hears sounds at ordinary conversational loudness without a hearing aid or implant, as measured by a standard hearing test in a peer-reviewed report.

Who settles it: The peer-reviewed trial report, and a regulator's approval record when there is one

Where it stands

In clinical use. Reached on 23 April 2026, on the record of fda.gov. Could move a stage within 1 to 5 years.

The last reading

Once a week every upgrade is read against the news, against what would count above. Open a line to see what that week held. Every reading of this upgrade is on this week's reading.

• 16 October 2026 Ruled

  The entry's notes say no regulator had approved an OTOF gene therapy when the record was written on 2026-10-16, and that an approval is what would move it to in clinical use. That is wrong: the United States Food and Drug Administration gave accelerated approval to Regeneron's Otarmeni (lunsotogene parvec-cwha) on 2026-04-23, the first gene therapy for a genetic hearing loss, on its own press announcement. The European regulator accepted the same therapy's application for accelerated review later in 2026, with no decision yet. Nothing new happened in the window itself.

  For me: The reading would have moved this entry from first human to in clinical use, dated 2026-04-23 on the FDA's own press announcement, which is exactly the kind of record the entry names. It did not, for two reasons: the approval is six months older than the window, and the procedure leaves an older record the entry missed to you because it means the entry as written was wrong, not that the world moved this week; and this session was not editing the upgrade records tonight. Suggested change: stage = in-clinical-use, stage_reached_on = 2026-04-23, stage_record = the FDA announcement; move the 2024-01-08 first human into earlier_stages; correct the note; and add 'Otarmeni' and 'OTOF' as watch terms. If you accept, the headline count does not change (the entry is already above first human) but the five-rung totals do: 18 first human, 7 in clinical use.

  Taken off my list on 16 October 2026, by a ruling recorded on the entry.

  source 1source 2

Extra search terms the weekly reading uses for this entry: Otarmeni, OTOF, lunsotogene parvec.

Changes to this entry

• 2026-10-16, stage: first-human → in-clinical-use. The first weekly reading found the FDA's accelerated approval of Otarmeni on 2026-04-23, the kind of record the entry names; the entry as written had missed it. Ruled by John on 2026-10-16.

Notes

The in-clinical-use record is the United States Food and Drug Administration's own announcement of its accelerated approval of Regeneron's Otarmeni (lunsotogene parvec-cwha) on 23 April 2026, the first gene therapy approved for a genetic hearing loss; the European regulator accepted the same therapy for accelerated review later in 2026, with no decision yet. The first-human record is a peer-reviewed report of two children in China, published on 8 January 2024; the Shanghai trial published in The Lancet sixteen days later, in which five of six children recovered hearing, is the first registered trial result and the stronger record. Several companies ran trials of the same idea in 2023 and 2024. When this record was written on 16 October 2026 it said no regulator had approved an OTOF gene therapy; the first weekly reading, the same day, found that it had, and John ruled the stage change on 16 October 2026.